Coya Therapeutics (COYA) vs Corbus Pharmaceuticals (CRBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Coya Therapeutics (COYA) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 20.9% versus a loss of 60.7%. Coya Therapeutics is the larger company by market cap ($118.3 million vs $100.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | CRBP |
|---|---|---|
| Share price | $5.04 | $5.22 |
| Market cap | $118.29M | $100.86M |
| 1-day change | +1.07% | -1.04% |
| YTD return | -13.97% | -35.26% |
| 1-year return | -20.92% | -60.73% |
| 5-year return | — | -82.78% |
| EPS (TTM) | $-1.07 | $-6.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $20.56 |
| 52-week low | $3.71 | $5.13 |
| Distance from 52-week high | -34.93% | -74.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +201.62% | +552.54% |
| Average volume | 158.05K | 756.54K |
| Shares outstanding | 23.46M | 19.34M |
| Employees | 8 | 36 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed CRBP by 39.8 percentage points over the past year.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
COYA vs CRBP FAQ
Which is bigger, Coya Therapeutics or Corbus Pharmaceuticals?
Coya Therapeutics (COYA) is larger, with a market capitalization of $118.29M compared with $100.86M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, COYA or CRBP?
COYA returned -20.92% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Corbus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.